Duofilm Liquid
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle |
|---|---|
| Acide lactique | 16,7 % |
Nicht arzneiliche Inhaltsstoffe
Flexible collodion
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Sous-population S/O | Non précisée | 1 Goutte(s) | 24 heures |
In Kanada zugelassene Verwendungen
For the removal of common warts.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : DUOFILM® is for external use only. DUOFILM® is extremely flammable and should be kept away from fire or flame. Keep bottle tightly capped when not in use. Store at controlled room temperature away from heat. Patients should be advised not to inhale the vapour. DUOFILM® may cause eye irritation. Avoid contact with eyes and other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, flush with water for 15 minutes. If discomfort persists, patients should be advised to contact a physician. Avoid exposure to healthy skin. DUOFILM® may cause skin irritation. If undue skin irritation develops, treatment should be discontinued and patients should be advised to contact a physician or pharmacist. Consider alternative treatments if warts cover a large area of the body (more than 5 cm²) due to the potential risk of salicylate toxicity. DUOFILM® is not recommended in patients with peripheral neuropathy except under the supervision of a physician. Oral salicylates taken during or immediately after a viral illness have been associated with Reye's syndrome and hence there is a theoretical risk with topical salicylates. Therefore, do not use in children or teenagers during or immediately after chickenpox, influenza, or other viral infections. It has been reported that salicylates are excreted via breast milk. Patients should be advised to consult a health care physician if discomfort persists. Keep out of the sight and reach of children. Pregnancy and Lactation Pregnancy The safety of DUOFILM® during human pregnancy has not been established. Studies in animals given salicylic acid orally demonstrated embryo-toxicity at high doses. DUOFILM® is not recommended during pregnancy. Lactation Salicylates are excreted in human milk. DUOFILM® is not recommended during lactation. If used or administered during lactation, care should be taken to avoid contact with the breast area in order to avoid accidental ingestion by the infant.
Originaltext auf Englisch.
Known Adverse Reactions : Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (greater than and or equal to 1/10), common (greater than and or equal to 1/100 to less than 1/10), uncommon (greater than and or equal to 1/1000 to less than 1/100) rare (greater than and or equal to 1/10000 to less than 1/1000) and very rare (less than 1/10000). Clinical Trial Data Immune system disorders Common: Rash Skin and subcutaneous tissue disorders Very common: Application site reaction, pruritus, burning sensation, erythema, scaling, dryness Common: Skin hypertrophy Post-marketing data Immune system disorders Rare: Application site hypersensitivity including inflammation Skin and subcutaneous tissue disorders Rare: Application site pain and irritation. Application site discoloration/skin discoloration. Exposure to healthy skin can lead to application site blistering and skin exfoliation. Allergic dermatitis. Interactions DUOFILM® may increase the absorption of other topically applied medicines. Therefore, concomitant use of DUOFILM® and other topical medicines on the treated area should be avoided.
Originaltext auf Englisch.
Produktdaten
- Inhaber
- Haleon US Holdings LLC
- NPN oder DIN-HM
- 00370576
- Status
- Lizenz nicht aktiv
- Lizenzdatum
- 30. November 2009
- Überarbeitungsdatum
- 21. Februar 2017
- Form
- Solution semblabe au collodion.
- Verabreichungsweg
- Topique
- Art des Antrags
- DIN de transition
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 00370576
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.